Charles Sternberg, Associate Editor01.05.24
Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), has welcomed Dave Amerson to its Board of Directors.
“Dave has established an unrivaled track record of successful commercialization of new medical device technologies,” said Anton Clifford, Ph.D., founder and CEO of Moximed. “His unique perspective and experience bringing game-changing med-tech solutions to market are timely additions to our Board as we accelerate our commercialization of the MISHA™ Knee System in the United States. We are excited to welcome him to our Board.”
“I am thrilled to join Moximed’s Board of Directors at this exciting point in the company’s commercial trajectory,” said Amerson. “The parallels I see between Moximed and my experience successfully leading and advising other disruptive med-tech companies is compelling. Moximed has developed a unique, patient-centered solution to a massive clinical problem. The company reports excellent clinical outcomes, has FDA market authorization, and is now seeing tremendous surgeon and patient interest in the MISHA Knee System. I’m excited to work with Anton and the team to help more patients gain access to the technology and to similarly contribute to Moximed’s future success."
He served as President and Chief Executive Officer of NeoTract, Inc., which was acquired by Teleflex in 2017 in a transaction valued at up to $1.1 billion. In addition, Amerson served on the Board of Directors for Relievant Medsytems, Inc., which was acquired by Boston Scientific Corporation in 2023 for an upfront cash payment of $850 million and undisclosed additional payments based on commercial milestones.
He also served as Chairman of the Board of Palette Life Sciences, which was acquired by Teleflex in 2023 for an upfront cash payment of $600 million and an additional $50 million based on certain milestones.
Amerson joins Josh Makower (Chairman), Anton Clifford, Arthur Franken, Shahzad Malik, Matt McAviney, Hank Plain, Kevin Sidow, Brigitte Smith, and David van Meter on Moximed’s Board of Directors.
“Dave has established an unrivaled track record of successful commercialization of new medical device technologies,” said Anton Clifford, Ph.D., founder and CEO of Moximed. “His unique perspective and experience bringing game-changing med-tech solutions to market are timely additions to our Board as we accelerate our commercialization of the MISHA™ Knee System in the United States. We are excited to welcome him to our Board.”
“I am thrilled to join Moximed’s Board of Directors at this exciting point in the company’s commercial trajectory,” said Amerson. “The parallels I see between Moximed and my experience successfully leading and advising other disruptive med-tech companies is compelling. Moximed has developed a unique, patient-centered solution to a massive clinical problem. The company reports excellent clinical outcomes, has FDA market authorization, and is now seeing tremendous surgeon and patient interest in the MISHA Knee System. I’m excited to work with Anton and the team to help more patients gain access to the technology and to similarly contribute to Moximed’s future success."
Experience
Amerson has over three decades of leadership experience and nearly $3 billion of M&A transactions in medical devices as a CEO or as an active board member.He served as President and Chief Executive Officer of NeoTract, Inc., which was acquired by Teleflex in 2017 in a transaction valued at up to $1.1 billion. In addition, Amerson served on the Board of Directors for Relievant Medsytems, Inc., which was acquired by Boston Scientific Corporation in 2023 for an upfront cash payment of $850 million and undisclosed additional payments based on commercial milestones.
He also served as Chairman of the Board of Palette Life Sciences, which was acquired by Teleflex in 2023 for an upfront cash payment of $600 million and an additional $50 million based on certain milestones.
Amerson joins Josh Makower (Chairman), Anton Clifford, Arthur Franken, Shahzad Malik, Matt McAviney, Hank Plain, Kevin Sidow, Brigitte Smith, and David van Meter on Moximed’s Board of Directors.